xml version="1.0" encoding="utf-8" ?   8-K   

   AMGEN INC false 0000318154        0000318154   2022-02-17 2022-02-17     0000318154  us-gaap:CommonStockMember    2022-02-17 2022-02-17     0000318154  us-gaap:SeniorNotesMember    2022-02-17 2022-02-17      

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549 

Form 8-K 

CURRENT REPORT 

Pursuant to Section 13 OR 15(d) 

of the Securities Exchange Act of 1934 

Date of Report (Date of earliest event reported): February 17, 2022 

 Amgen Inc.  

(Exact name of registrant as specified in its charter) 

  [DATA_TABLE_REMOVED] 

  [DATA_TABLE_REMOVED] 

Registrant’s telephone number, including area code 

(805) 447-1000 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: 

   ☐  

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

   ☐  

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

  [DATA_TABLE_REMOVED] 

  [DATA_TABLE_REMOVED] 

Securities registered pursuant to Section 12(b) of the Act: 

  [DATA_TABLE_REMOVED] 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). 

Emerging growth company ☐ 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 

 Item 1.01.  

Entry into a Material Definitive Agreement.  

On February 22, 2022, Amgen Inc. (the “Company”) issued and sold $750,000,000 aggregate principal amount of the Company’s 3.000% Senior Notes due 2029 (the “2029 Notes”), $1,000,000,000 aggregate principal amount of the Company’s 3.350% Senior Notes due 2032 (the “2032 Notes”), $1,000,000,000 aggregate principal amount of the Company’s 4.200% Senior Notes due 2052 (the “2052 Notes”), and $1,250,000,000 aggregate principal amount of the Company’s 4.400% Senior Notes due 2062 (the “2062 Notes” and, together with the 2029 Notes, the 2032 Notes and the 2052 Notes, the “Notes”). The Notes are registered under an effective Registration Statement on Form S-3 (Registration No. 333-236351) (the “Registration Statement”), filed on February 10, 2020, and were issued pursuant to an indenture, dated as of May 22, 2014 (the “Indenture”), between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee, and an officer’s certificate, dated as of February 22, 2022 (the “Officer’s Certificate”), setting forth the terms of the Notes. Net proceeds to the Company from the offering were approximately $3,949,135,700, after deducting underwriters’ discounts and estimated offering expenses payable by the Company.  

The relevant terms of the Notes are set forth in the Indenture, included as Exhibit 4.1 of the Company’s Current Report on Form 8-K, filed on May 22, 2014, and incorporated herein by reference, and the Officer’s Certificate (including the forms of the Notes) attached hereto as Exhibit 4.2 and incorporated herein by reference.  

The 2029 Notes will pay interest at the rate of 3.000% per annum, the 2032 Notes will pay interest at the rate of 3.350% per annum, the 2052 Notes will pay interest at the rate of 4.200% per annum and the 2062 Notes will pay interest at the rate of 4.400% per annum, which shall be payable in cash semi-annually in arrears on February 22 and August 22 of each year, beginning on August 22, 2022. The 2029 Notes will mature on February 22, 2029, the 2032 Notes will mature on February 22, 2032, the 2052 Notes will mature on February 22, 2052 and the 2062 Notes will mature on February 22, 2062.  

In the event of a change in control triggering event, as defined in the Officer’s Certificate, the holders of the Notes may require the Company to purchase for cash all or a portion of their Notes at a purchase price equal to 101% of the principal amount of Notes, plus accrued and unpaid interest, if any. The descriptions of the Indenture, the Officer’s Certificate and the Notes in this report are summaries and are qualified in their entirety by the terms of the Indenture, the Officer’s Certificate and the Notes, respectively.  

The Notes will rank equal in right of payment to all of the Company’s other existing and future senior unsecured indebtedness, senior in right of payment to all of the Company’s existing and future subordinated indebtedness, effectively subordinated in right of payment to all of the Company’s subsidiaries’ obligations (including secured and unsecured obligations) and subordinated in right of payment to the Company’s secured obligations, to the extent of the assets securing such obligations.   

 Item 9.01.  

Financial Statements and Exhibits.  

  [DATA_TABLE_REMOVED]  

SIGNATURE  

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.  

  [DATA_TABLE_REMOVED]